← Back to Home

Alzheimer’s Antibody Reaches Its Intended Target in Humans for the First Time, but Evidence of Efficacy Is Still Some Way Off

After a single infusion of PMN310, detectable amyloid beta oligomers in the cerebrospinal fluid of healthy participants decreased with increasing dose, adding early human evidence for its mechanism of action; this exploratory signal cannot yet answer whether the drug can slow cognitive decline.

By SURL BioNews

One challenge in developing new Alzheimer’s drugs is demonstrating that, after entering the central nervous system, a drug actually reaches the molecule it was designed to clear. ProMIS Neurosciences reported that after healthy adults received a single infusion of the experimental antibody PMN310, detectable amyloid beta oligomers in their cerebrospinal fluid decreased as the dose increased. This is a preliminary human signal that the drug “engaged its target,” but it is not evidence of improved memory or delayed disease progression.

The data come from the completed Phase 1a trial NCT06105528. This randomized, double-blind, placebo-controlled study enrolled 40 healthy adults and tested five single ascending doses ranging from 175 to 2,800 milligrams; researchers performed lumbar punctures on days 3 and 29 after dosing. The company said oligomer levels declined in a dose-dependent manner at both time points, while PMN310 exposure in cerebrospinal fluid increased approximately linearly with dose and had a half-life of about 27 days.

PMN310 is designed to recognize soluble amyloid beta oligomers while largely avoiding monomers, plaques, and deposits in blood vessel walls. This differs from anti-amyloid antibodies that primarily bind to plaques; the developer hopes that narrower selectivity can reduce unintended binding and lower the risk of amyloid-related imaging abnormalities (ARIA). However, this remains a hypothesis to be tested with clinical data, and the current results are not sufficient to compare the safety or efficacy of PMN310 with therapies already on the market.

Oligomers were measured using a surface-based fluorescence intensity distribution analysis developed by attyloid GmbH. This assay is currently an exploratory tool, and oligomer reduction was not a core objective of the 1a trial, which primarily focused on safety, tolerability, and pharmacokinetics. Healthy adults already have a lower oligomer burden, and the sample size was limited, so the findings still need to be confirmed in patient populations, in repeat-dosing settings, and in other laboratories.

### Background

In recent years, amyloid research has gradually shifted the question from “can plaques be removed?” to “which molecular form is most meaningful to remove?” Soluble oligomers are thought to potentially interfere more directly with neuronal function, but this study did not answer questions about how they should be measured in humans, their relationship to disease progression, or whether lowering their concentration can translate into cognitive benefit. In other words, PMN310 has currently taken a small step toward validating its pharmacological mechanism, rather than crossing the efficacy threshold.

The real test will come in the Phase 1b PRECISE-AD trial NCT06750432. The study plans to enroll 144 participants with mild cognitive impairment due to Alzheimer’s disease or mild dementia, randomly assigning them to receive PMN310 or placebo as an infusion every 28 days for a total of 12 infusions. Primary assessments include adverse events, ARIA, plasma p-tau217, and amyloid positron emission tomography; multiple measures of cognition and daily functioning are listed as preliminary efficacy endpoints. The trial registry has not yet posted results, so whether PMN310 can combine target selectivity, clinical safety, and real-world benefit remains an open question.

References

  1. ProMIS Neurosciences
  2. ProMIS Neurosciences
  3. ClinicalTrials.gov
  4. ClinicalTrials.gov